Assuring the quality of next-generation sequencing in clinical laboratory practice

Article metrics

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Clinical and Laboratory Standards Institute (CLSI). Quality management system: a model for laboratory services; approved guideline 4th edn. (Document no. GP26–A4, Vol. 31, No. 15) (Clinical and Laboratory Standards Institute, 2011).

  2. 2

    Centers for Medicare and Medicaid Services. Clinical laboratory improvement amendments of 1988 (Part 493) 1443–1495 (US Department of Health and Human Services, 1988).

  3. 3

    International Organization for Standardization. ISO 15189 Medical laboratories—Particular requirements for quality and competence (International Organization for Standardization, 2007).

  4. 4

    Clinical and Laboratory Standards Institute (CLSI). Molecular Methods for Clinical Genetics and Oncology Testing; Approved Guideline-Third Edition CLSI (Document MM01-A3, Vol 32, No. 7) (Clinical and Laboratory Standards Institute, 2012).

  5. 5

    Durbin, R.M. et al. Nature 467, 1061–1073 (2010).

Download references


The authors thank E. Mansfield, N. Aziz, P. Keller, J. Kaufman, S. Ghosh, R. Leach, J. Robinson, A. Felsenfeld, M. Salit and E. Highsmith for their help and support. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the CDC or the US Agency for Toxic Substances and Disease Registry. The identification of certain commercial equipment, instruments or materials in this document does not imply recommendation or endorsement by the US National Institute of Standards and Technology, nor does it imply that the products identified are necessarily the best available for the purpose. The research was supported in part by an appointment to A.S.G. to the Research Participation Program at the CDC administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and the CDC.

Author information

Correspondence to Ira M Lubin.

Ethics declarations

Competing interests

D.P.D. works at the Medical College of Wisconsin; T.H. works at Illumina; E.L. works at University of Utah/ARUP Laboratories, has research grants from NIH/NICHD and NHGRI and receives consulting fees from Novartis and Complete Genomics; E.L.H.C. worked at Emory University School of Medicine and now works at Baylor College of Medicine; J.G.C. works at GeneDX; D.H.F. works at Sequenom; M.R.F. works at and owns stock in Life Technologies; C.J.L. works at Softgenetics; M.G.R. works at and owns stock options/bonds and has ownership in Omicia; B.B.S. works at Life Sciences (Roche); J.M.Y. works at and owns stock in Illumina.

Supplementary information

Supplementary Text and Figures

Supplementary Guidelines, Supplementary Figure 1 and Supplementary Tables 1–4 (PDF 490 kb)

Rights and permissions

Reprints and Permissions

About this article

Further reading